🧠 Neuro MD #14 Poďme urobiť poriadok v protilátkach!

The article addresses vitamin B6 deficiency in Parkinson's disease patients treated with levodopa and carbidopa. The FDA documented 14 cases of seizures associated with B6 deficiency at levodopa doses exceeding 1,000 mg per day, with symptoms appearing 23 to 132 months after treatment initiation. Seizures typically have a focal character with secondary generalization and respond poorly to antiepileptic drugs but very well to vitamin B6 supplementation. Levodopa depletes vitamin B6 and carbidopa binds to it, further reducing its availability. The FDA recommends monitoring B6 levels before treatment initiation and regularly during therapy. The article further details the nomenclature and clinical associations of ganglioside antibodies in various forms of polyneuropathies, including Guillain-Barré syndrome and multifocal motor neuropathy. Finally, it provides practical recommendations for antibody testing in atypical CIDP presentations and nodopathies/paranodopathies.